Please try another search
Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States and China. The company provides Quetiapine XR for the treatment of Schizophrenia; and Dexlansoprazole DR capsules. It also develops ONCORE, a proprietary drug delivery technology that was developed to improve the patient compliance and safety of the tyrosine kinase inhibitor of oncology drugs; 505(b)(2)NDA, a therapeutic product; Tascenso ODT for the treatment of multiple sclerosis; and HND-033 and HND-027, an oncology products. In addition, the company develops HND-004, a diabetic drug; HND-032 for smoking cessation; and HND-026, a GI drug. Handa Pharmaceuticals, Inc. was founded in 2014 and is headquartered in Tainan City, Taiwan.
Name | Age | Since | Title |
---|---|---|---|
Xin-Fang Wu | - | - | Director |
Jinn Wu | 73 | - | Independent Director |
Will Wang | - | - | Independent Director |
Willie Lin | - | - | Independent Director |
Mei-Fang Chang | - | 2016 | Senior VP of Quality Affairs & Director |
Fang-Yu Liu | - | 2016 | Founder & Chairman |
Toshiyo Chen | - | - | GM & Director |
Jo Shen | - | - | Director |
Shao-Li Hsu | - | - | Member of the Supervisory Board |
Chun-De Weng | - | - | Member of the Supervisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review